Reply To: Bristol Myers Squibb Acquisition of Celgene

Home › Fairmark Forum › Taxation of Investments › Bristol Myers Squibb Acquisition of Celgene › Reply To: Bristol Myers Squibb Acquisition of Celgene

March 5, 2020 at 11:48 pm #5319
FinancialPlan
Participant

The fair market value of the Celgene stock was $34,569.60 on 11/21/19. The cost basis was $4117.85.

After Bristol Myers Squibb acquired Celgene, the fair market value of the Bristol Myers Squibb stock was $18,220.80 on 11/21/19. The cost basis was $1,7880.

I received $16,000 in cash as a result of the merger.

How do I compute my tax liability?